Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (8): 50-53.doi: 10.6040/j.issn.1671-7554.0.2023.0280

• 临床医学 • Previous Articles    

Clinical efficacy of Budesonide/Formoterol in the treatment of SARS-CoV-2-associated cough

WANG Junren, LI Daowei, WANG Xingguang, JIANG Shujuan   

  1. Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
  • Published:2023-08-30

PDF (PC)

171

Abstract: Objective To observe the efficacy and safety of Budesonide/Formoterol in the treatment of SARS-CoV-2-associated cough. Methods Clinical data of patients with acute or subacute cough after SARS-CoV-2 infection who received Budesonide/Formoterol(160 μg∶ 4.5 μg)during Dec. 1, 2022 and Jan. 30, 2023 were retrospectively analyzed. Severity of cough was evaluated with visual analogue scale(VAS). Results A total of 168 patients were involved, including 73 males and 95 females. The patients aged 18 to 80 years, average(47.02±15.13)years. Cough duration ranged from 5 to 60 days, average(26.18±12.62)days. The total effective rate of treatment was 84.51%, and the cough symptoms significantly improved after an average of(5.29±2.45)days of treatment. After treatment, the VAS score decreased from(5.91±1.77)to(1.35±2.12),(P<0.001). Mild adverse reactions such as voice hoarse, headache and palpitation occurred in 5 cases, with an adverse reaction rate of 2.98%. No serious adverse reactions occurred. Conclusion Budesonide/Formoterol has a significant clinical effect in the treatment of cough after SARS-CoV-2 infection and can quickly relieve cough symptoms, which has clinical application value.

Key words: SARS-CoV-2 infection, Acute cough, Subacute cough, Budesonide/Formoterol, Treatment

CLC Number: 

  • R562.2+1
[1] 中华医学会呼吸病学分会哮喘学组. 咳嗽的诊断与治疗指南(2021)[J]. 中华结核和呼吸杂志, 2022, 45(1):13-46. Asthma Group of Chinese Thoracic Society. Chinese national guideline on diagnosis and management of cough(2021)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2022, 45(1):13-46.
[2] Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome:role of viral neurotropism, neuroinflammation, and neuroimmune responses[J]. Lancet Respir Med, 2021, 9(5):533-544.
[3] Marquez C, Kerkhoff AD, Schrom J, et al. COVID-19 symptoms and duration of rapid antigen test positivity at a community testing and surveillance site during pre-delta, delta, and Omicron BA.1 periods[J]. JAMA Netw Open, 2022, 5(10):e2235844. doi:10.1001/jamanetworkopen.2022.35844.
[4] Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study[J]. Lancet, 2020, 395(10229):1054-1062.
[5] Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance:a prospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335):1618-1624.
[6] Barry M, Althabit N, Akkielah L, et al. Clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak of the pandemic[J]. Int J Infect Dis, 2021, 106:43-51. doi:10.1016/j.ijid.2021.03.058.
[7] Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK(PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial[J]. Lancet, 2021, 398(10303):843-855.
[8] Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial[J]. Lancet Respir Med, 2021, 9(7):763-772.
[9] Baker JR, Mahdi M, Nicolau DV Jr, et al. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids:a mechanistic analysis[J]. Lancet Respir Med, 2022, 10(6):545-556.
[10] Lee TC, Bortolussi-Courval É, Belga S, et al. Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis[J]. Eur Respir J, 2022, 59(5):2102921. doi:10.1183/13993003.02921-2021.
[11] 中华医学会呼吸病学分会, 国家呼吸医学中心, 赖克方. 新型冠状病毒感染咳嗽的诊断与治疗专家共识[J]. 中华结核和呼吸杂志, 2023, 46(3):217-227. Chinese Thoracic Society, National Center for Respiratory Medicine, LAI Kefang. Expert consensus on the diagnosis and treatment of SARS-CoV-2-associated cough[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2023, 46(3):217-227.
[12] Sun JY, Zhan C, Deng Z, et al. Expression of interferon-γ and its effect on cough hypersensitivity in chronic refractory cough patients[J]. Thorax, 2022, 77(6):621-624.
[13] Deng Z, Zhou WL, Sun JY, et al. IFN-γ enhances the cough reflex sensitivity via calcium influx in vagal sensory neurons[J]. Am J Respir Crit Care Med, 2018, 198(7):868-879.
[14] Deng Z, Ding WB, Li FY, et al. Pulmonary IFN-γ causes lymphocytic inflammation and cough hypersensitivity by increasing the number of IFN-γ-secreting T lymphocytes[J]. Allergy Asthma Immunol Res, 2022, 14(6):653-673.
[15] Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells[J]. J Virol, 2020, 95(1):e01648-e01620.
[16] Heinen N, Meister TL, Klöhn M, et al. Antiviral effect of budesonide against SARS-CoV-2[J]. Viruses, 2021, 13(7):1411. doi:10.3390/v13071411.
[17] Kim SR, Song JH, Ahn JH, et al. Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation[J]. Antiviral Res, 2018, 151:87-96. doi:10.1016/j.antiviral.2018.01.012.
[18] Nicolau DV, Bafadhel M. Inhaled corticosteroids in virus pandemics:a treatment for COVID-19?[J]. Lancet Respir Med, 2020, 8(9):846-847.
[19] Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids[J]. Am J Respir Crit Care Med, 2020, 202(1):83-90.
[20] Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues[J]. Cell, 2020, 181(5):1016-1035.e19.
[21] Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon[J]. J Allergy Clin Immunol, 2021, 147(2):510-519.e5.
[22] Skevaki CL, Christodoulou I, Spyridaki IS, et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus[J]. Clin Exp Allergy, 2009, 39(11):1700-1710.
[23] Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells[J]. Respir Investig, 2020, 58(3):155-168.
[1] Lin HUANG,Zhen CHE,Ming LI,Yuxi LI,Qing NING. Research advances of artificial intelligence in the diagnosis and treatment of orthopaedic diseases [J]. Journal of Shandong University (Health Sciences), 2023, 61(3): 37-45.
[2] MA Chenbang, GAO Pei, CHANG Yao, MAO Changlin, CHEN Feng, ZHU Kejia, GUAN Yong, LI Shanjun, DING Sentai. A case of non-tuberous sclerosis complex with giant angiomyolipoma of both kidneys treated with simultaneous resection and literature review [J]. Journal of Shandong University (Health Sciences), 2023, 61(2): 65-71.
[3] ZENG Yanping, YAN Shengtao, LIU Xiaoyu, JIANG Ziqing. A case report of parathyroid carcinoma with parathyroid crisis as the primary clinical manifestation [J]. Journal of Shandong University (Health Sciences), 2023, 61(1): 62-68.
[4] JIANG Ziqing, ZENG Yanping, JI Xiaodong, ZUO Junling. A case report of hemophagocytic syndrome secondary to talaromyces marneffei infection [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 91-97.
[5] PENG Chao, ZHOU Yingfang. Progress on the medical treatment of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 20-25.
[6] KONG Xinxin, SUN Shuzhen, LI Qian, CHEN Yuan, ZHOU Aihua, WANG Li, YAO Xiujun. Analysis of 7 cases of anti-H factor antibody-positive hemolytic uremic syndrome [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 82-86.
[7] SONG Yufeng, NING Hao, YAO Zhigang, WU Haihu, LIU Feifan, LYU Jiaju. Clinical and imaging features of adrenal cavernous hemangioma [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 37-42.
[8] PAN Pengfei, XU Lisheng, JI Kunqian, WANG Dexiang, LI Yu. Mitochondrial myopathy beginning with respiratory failure: one case and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 54-59.
[9] JIN Lujun, LIN Xueyan, LIU Tianhang, LI Qing, LI Xiaowen, FANG Lei, SUN Hao, TIAN Yongjie. Influencing factors of the choice of treatment for patients with severe pelvic organ prolapse [J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 39-43.
[10] Guowei CHE. It is necessary for enhanced recovery after surgery to keep pace with the times [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 17-22.
[11] SHI Xiaohan, LI Huayu, LI Feng. Prognostic factors of elderly patients with glioblastoma treated with Stupp treatment [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 42-48.
[12] DING Zichen, WANG Haohua, ZHOU Liwen, CONG Huiwen, LI Chengsheng, BAO Qihan, YANG Yi, WANG Lianyuan, WANG Suzhen, SHI Fuyan. Study on the individualized efficacy for non-small cell lung cancer patients based on Bayesian Additive Regression Tree model [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 92-98.
[13] WANG Yifeng, HE Liqing. Research progress on surgery of inguinal lymph nodes in vulvar cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 103-109.
[14] HA Chunfang, LI Ruyue. Research progress of drug resistance in ovarian cancer and targeted therapy strategy [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 117-123.
[15] WANG Kefang, WU Chen. Dilemmas and thoughts on solutions of adherence to chronic disease management [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 124-129.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd